Skip to main content
SpringerLink
Log in

Vorderabschnittbefund mit weitreichenden Folgen

Anterior segment findings with far-reaching consequences

  • Bild und Fall
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Allen LE, Cosgrave EM, Kersey JP, Ramaswami U (2010) Fabry disease in children: correlation between ocular manifestations, genotyme and systemic clinical activity. Br J Ophthalmol 94:1602–1605

    Article  CAS  PubMed  Google Scholar 

  2. Beck M (2009) Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 9:255–261

    Article  CAS  PubMed  Google Scholar 

  3. Elstein D, Altarescu G, Beck M (2010) Fabry Disease. Springer, Dordrecht S 21–24

    Book  Google Scholar 

  4. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabryʼs disease. N Engl J Med 345:9–16

    Article  CAS  PubMed  Google Scholar 

  5. Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilol 42:187–200

    Article  Google Scholar 

  6. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30

    Article  PubMed  PubMed Central  Google Scholar 

  7. Germain DP, Benistan K, Angelova L (2010) X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne 31:209–213

    Article  Google Scholar 

  8. Germain DP, Charrow J, Desnick RJ et al (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52:353–358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hoffmann B, Mayatepek E (2009) Fabry disease-often seen, rarely diagnosed. Dtsch Arztebl Int 106:440–447

    PubMed  PubMed Central  Google Scholar 

  10. Keating GM, Simpson D (2007) Spotlight on agalsidase beta in Fabry disease. BioDrugs 21:269–271

    Article  CAS  PubMed  Google Scholar 

  11. Maier EM, Osterrieder S, Whybra C et al (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 95:30–38

    Article  PubMed  Google Scholar 

  12. Nguyen TT, Gin T, Nicholls K et al (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33:164–168

    Article  PubMed  Google Scholar 

  13. Pitz S, Kalkum G, Arash L et al (2015) Ocular sings correlate well with disease severety and genotype in Fabry disease. PLos One 10:e0120814

    Article  PubMed  PubMed Central  Google Scholar 

  14. Schiffmann R, Warnock DG et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2101–2111

    Article  Google Scholar 

  15. Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299–307

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Augenheilkunde, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Baldingerstraße, Marburg, 35043, Deutschland

    V. Besgen & Y. Wenner

  2. Klinik für Augenheilkunde, Klinikum der Goethe-Universität, Frankfurt am Main, Deutschland

    Y. Wenner

  3. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Deutschland

    P. Seipelt

Authors
  1. V. Besgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Seipelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Wenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Besgen.

Ethics declarations

Interessenkonflikt

V. Besgen, P. Seipelt und Y. Wenner geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht mündigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.

Additional information

Die Ergebnisse wurde auf dem DOG Genetic Symposium in Gießen 2014 publiziert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Besgen, V., Seipelt, P. & Wenner, Y. Vorderabschnittbefund mit weitreichenden Folgen. Ophthalmologe 113, 873–875 (2016). https://doi.org/10.1007/s00347-016-0232-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-016-0232-x

Search

Navigation